Clinical Trials on TTR Cardiomyopathy

Total 1250 results

Pfizer

Completed

Safety And Efficacy Evaluation Of Fx-1006a In Patients With V122i Or Wild-Type Transthyretin (TTR) Amyloid Cardiomyopathy

ATTR-CM | TTR-CM

United States
Pfizer

Completed

Safety And Pharmacokinetic Assessment Of Orally Administered Tafamidis In Healthy Volunteers

TTR Cardiomyopathy

Singapore
Pfizer

Completed

A Study To Determine Any Effect Of Tafamidis On Electrocardiographic Intervals, Specifically The Rate Corrected QT Interval (QTc)

TTR Cardiomyopathy

United States, Singapore, Belgium
Pfizer

Completed

Safety and Efficacy of Tafamidis in Patients With Transthyretin Cardiomyopathy (ATTR-ACT)

Transthyretin (TTR) Amyloid Cardiomyopathy

United States, Spain, Czechia, Canada, Belgium, Netherlands, Germany, Japan, France, United Kingdom, Brazil, Italy, Sweden
Pfizer

Completed

Long-term Safety of Tafamidis in Subjects With Transthyretin Cardiomyopathy

Transthyretin (TTR) Amyloid Cardiomyopathy

United States, Taiwan, Canada, Belgium, Australia, Czechia, Sweden, Spain, Italy, Hong Kong, Germany, Netherlands, United Kingdom, France, Japan, Argentina, Brazil
Pfizer

Recruiting

Vyndaqel Capsules Special Investigation (ATTR-CM)

Transthyretin (TTR) Amyloid Cardiomyopathy

Japan
Ionis Pharmaceuticals, Inc.
AstraZeneca

Active, not recruiting

The CARDIO-TTRansform Scintigraphy Sub-study

Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)

United States, Spain
Pfizer

Completed

Burden of Disease Study In Patients With Transthyretin Familial Amyloidosis Polyneuropathy (TTR-FAP) orTransthyretin Cardiomyopathy (TTR-CM) And Caregivers

Transthyretin Familial Amyloidosis Polyneuropathy (TTR-FAP) | Transthyretin Cardiomyopathy (TTR-CM) | Familial Amyloid Cardiomyopathy | Senile Systemic Amyloidosis (SSA)
Ensho Health Intelligent Systems Inc.

Enrolling by invitation

A Prospective Study to Assess the Utility of CA-4F in a Canadian Cardiology Setting

Transthyretin Amyloid Cardiomyopathy ("ATTR-CM")

Canada
Alnylam Pharmaceuticals

No longer available

Expanded Access Protocol to Provide Patisiran to Patients With Transthyretin-mediated Amyloidosis With Cardiomyopathy

Transthyretin-mediated Amyloidosis With Cardiomyopathy | ATTR Amyloidosis With Cardiomyopathy

United States
Ionis Pharmaceuticals, Inc.
AstraZeneca

Active, not recruiting

CARDIO-TTRansform Magnetic Resonance Imaging (MRI) Sub-study

Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)

United States, United Kingdom, Italy, Spain
Rigshospitalet, Denmark

Completed

Moderate Intensity Training in Patients With Truncating Genetic Variants in TTN.

Cardiomyopathies | TTN | Truncation Mutation

Denmark
Thibaud Damy

Completed

Prevalence of Transthyretin Amyloidosis in Hypertrophic Cardiomyopathy (Amylo)

Cardiac Amyloidosis | Hypertrophic Cardiomyopathy (HCM) | Amyloidosis in Transthyretin (TTR)

France
Medical University of Graz
Medical University Innsbruck

Recruiting

Association Between Lifetime Physical Activity and Exercise and the Development of Wild-type Transthyretin Amyloid Cardiomyopathy

Amyloid Cardiomyopathy | Wild Type ATTR Amyloidosis

Austria
Eidos Therapeutics, a BridgeBio company

Completed

Study of AG10 in Amyloid Cardiomyopathy

Familial ATTR-CM (ATTRm-CM, or FAC) | Wild-type ATTR-CM (ATTRwt-CM)

United States
Pfizer

Recruiting

Korean Post-marketing Surveillance Vyndamax® Capsules for the Treatment of Transthyretin Amyloid Cardiomyopathy

ATTR-CM (Transthyretin Amyloid Cardiomyopathy)

Korea, Republic of
Novo Nordisk A/S

Active, not recruiting

A Research Study to Look at How a New Medicine Called NNC6019-0001 Works and How Safe it is for People Who Have Heart Disease Due to Transthyretin (TTR) Amyloidosis

Transthyretin Amyloid Cardiomyopathy (ATTR CM)

United States, Netherlands, Spain, Portugal, Canada, Czechia, France, Germany, Italy, Japan
Mahidol University
Pfizer

Not yet recruiting

Thailand ATTR-CM Registry

Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

Thailand
Novo Nordisk A/S

Recruiting

A Research Study to Look at Long-term Treatment With a Medicine Called NNC6019-0001 for People Who Have Heart Failure Due to Transthyretin Amyloidosis

Transthyretin Amyloid Cardiomyopathy (ATTR CM)

United States, Netherlands, Germany, Canada, Czechia, France, Italy, Portugal, Spain
Ionis Pharmaceuticals, Inc.
AstraZeneca

Recruiting

An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)

Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)

United States, Austria, Belgium, Canada, France, Germany, Israel, Italy, Portugal, Spain, Sweden, United Kingdom, Australia, Greece
Ionis Pharmaceuticals, Inc.

Active, not recruiting

CARDIO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)

Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)

United States, Australia, Spain, Canada, Germany, Japan, Italy, Israel, Argentina, France, Portugal, Austria, Brazil, Greece, United Kingdom, Czechia, Sweden, Belgium, Denmark, Poland, Puerto Rico
Medical University of Vienna

Not yet recruiting

Edge-to-edge Mitral Valve Repair in ATTR-CM (MILLENNIAL)

Mitral Regurgitation | ATTR-Cardiomyopathy | Edge-to-Edge Mitral Valve Repair
Pfizer

Completed

A Retrospective Validation Study To Identify Chart-Based Clinical Diagnosis Of Wild-Type Transthyretin Amyloid Cardiomyopathy (Attrwt-CM) And Non-Amyloid Heart Failure Among Patients With Heart Failure (HF).

ATTR-CM

United States
Paolo Milani

Recruiting

NatiOnal Referral cenTEr Study of Transthyretin Amyloid Cardiomyopathy(ATTR) Patients on Tafamidis (NOTE-ATTR)

Amyloidosis | Amyloidosis Cardiac | ATTR Amyloidosis Wild Type

Italy
Steen Hvitfeldt Poulsen

Recruiting

Haemodynamic Effects of Dobutamine in Patients With Wild-type Transthyretin Amyloid Cardiomyopathy (ATTRwt) (DobATTR)

ATTR Amyloidosis Wild Type

Denmark
Mayo Clinic

Completed

Long-term Monitoring of Patients With Cardiac Amyloidosis With Implantable Event Monitors

TTR Cardiac Amyloidosis

United States
Alnylam Pharmaceuticals

Completed

A Study of the Safety, Tolerability and Pharmacokinetics of ALN-TTR02 in Japanese Healthy Volunteers

Transthyretin (TTR)-Mediated Amyloidosis

United Kingdom
CENTOGENE GmbH Rostock
Alnylam Pharmaceuticals

Recruiting

TRAMmoniTTR Study Genetic Screening of an At-risk Population for hATTR and Monitoring of TTR Positive Subjects (TRAMmoniTTR)

Cardiomyopathies | Polyneuropathies | Transthyretin Amyloidosis | Transthyretin-Related (ATTR) Familial Amyloid Cardiomyopathy | Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy

Germany, Austria, Switzerland
Columbia University
National Institute on Aging (NIA)

Recruiting

Analysis of Lumbar Spine Stenosis Specimens for Identification of Transthyretin Cardiac Amyloidosis

Lumbar Spinal Stenosis | Cardiomyopathy, Hypertrophic | Cardiac Amyloidosis | ATTR Amyloidosis Wild Type | ATTR Gene Mutation | ATTRV122I Amyloidosis

United States
Alnylam Pharmaceuticals

Completed

The Study of ALN-TTR02 (Patisiran) for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Patients Who Have Already Been Treated With ALN-TTR02 (Patisiran)

TTR-mediated Amyloidosis

Portugal, Sweden, Brazil, United States, France, Spain, Germany
Alnylam Pharmaceuticals

Completed

Safety and Tolerability of Patisiran (ALN-TTR02) in Transthyretin (TTR) Amyloidosis

TTR-mediated Amyloidosis

Portugal, Spain, Sweden, Brazil, United States, France, Germany
IRCCS Policlinico S. Matteo

Completed

A Study of Doxycycline and Tauroursodeoxycholic Acid (Doxy/TUDCA) Plus Standard Supportive Therapy Versus Standard Supportive Therapy Alone in Cardiac Amyloidosis Caused by Transthyretin

TTR Cardiac Amyloidosis

Italy
Alnylam Pharmaceuticals

Completed

A Phase 1, Single- and Multi-Dose, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered ALN-TTRSC (Revusiran) in Healthy Volunteers

TTR-mediated Amyloidosis

United Kingdom
Alnylam Pharmaceuticals

Completed

Trial to Evaluate Safety, Tolerability, and Parmacokinetics of ALN-TTR02 in Healthy Volunteer Subjects

TTR-mediated Amyloidosis

United Kingdom
University of Texas Southwestern Medical Center
National Heart, Lung, and Blood Institute (NHLBI); Columbia University; The Cleveland... and other collaborators

Recruiting

Subclinical Transthyretin Cardiac Amyloidosis in V122I TTR Carriers

Amyloidosis, Familial | Amyloidosis, Hereditary | Amyloidosis Cardiac | Transthyretin-Related (ATTR) Familial Amyloid Cardiomyopathy | Transthyretin Gene Mutation

United States
Alnylam Pharmaceuticals

Completed

A Extension Study to Evaluate Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Cardiac Amyloidosis

TTR-mediated Amyloidosis

United States, Canada, United Kingdom
Alnylam Pharmaceuticals

Completed

ENDEAVOUR: Phase 3 Multicenter Study of Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)

Amyloid Neuropathies | Amyloid Neuropathies, Familial | Amyloidosis, Hereditary | Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC) | Amyloidosis, Hereditary, Transthyretin-Related | Familial Transthyretin Cardiac Amyloidosis

United States, France, Italy, Spain, Canada, Germany, Belgium, Sweden, United Kingdom
Alnylam Pharmaceuticals

Completed

Phase 2 Study to Evaluate ALN-TTRSC (Revusiran) in Patients With Transthyretin (TTR) Cardiac Amyloidosis

TTR-mediated Amyloidosis

United States, United Kingdom
Intellia Therapeutics

Recruiting

Long-Term Follow-Up (LTFU) of Subjects Dosed With NTLA-2001

Transthyretin-Related (ATTR) Familial Amyloid Cardiomyopathy | Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy | Wild-Type Transthyretin Cardiac Amyloidosis

United Kingdom, New Zealand, Sweden
Intellia Therapeutics

Active, not recruiting

Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NTLA-2001 in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy (ATTRv-PN) and Patients With Transthyretin Amyloidosis-Related Cardiomyopathy (ATTR-CM)

Transthyretin-Related (ATTR) Familial Amyloid Cardiomyopathy | Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy | Wild-Type Transthyretin Cardiac Amyloidosis

France, United Kingdom, New Zealand, Sweden
University of Aberdeen
NHS Grampian

Completed

Persistent Symptoms and Early Incomplete Recovery After Acute Stress-induced Cardiomyopathy: Is There Ongoing Heart Distress? The HEROIC Study (HEROIC)

Tako-tsubo Cardiomyopathy

United Kingdom
Midwest Heart & Vascular Specialists

Recruiting

Amyloidosis Incidence in High-Risk Cardiac Device Patients

AL Amyloidosis | Amyloid | Cardiac Amyloidosis | Amyloidosis Cardiac | Systemic Amyloidosis | ATTR Amyloidosis Wild Type | Infiltrative Cardiomyopathy, Amyloid

United States
University of California, Irvine

Withdrawn

The Genetics of Cardiomyopathy and Heart Failure

Dilated Cardiomyopathy | Hypertrophic Cardiomyopathy | Restrictive Cardiomyopathy | Mitochondrial Cardiomyopathy | Noncompaction Cardiomyopathy

United States
Capricor Inc.
National Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health... and other collaborators

Unknown

Dilated cardiomYopathy iNtervention With Allogeneic MyocardIally-regenerative Cells (DYNAMIC) (DYNAMIC)

Heart Failure | Ischemic Cardiomyopathy | Nonischemic Cardiomyopathy | Dilated Cardiomyopathy (DCM)

United States
Alnylam Pharmaceuticals

Active, not recruiting

APOLLO-B: A Study to Evaluate Patisiran in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy)

Transthyretin Amyloidosis (ATTR) With Cardiomyopathy

United States, Australia, Brazil, Bulgaria, France, Italy, Japan, Mexico, Netherlands, Taiwan, United Kingdom, Belgium, Czechia, Denmark, New Zealand, Sweden, Korea, Republic of, Argentina, Chile, Hong Kong, Portugal
Alnylam Pharmaceuticals

Active, not recruiting

HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

Transthyretin Amyloidosis (ATTR) With Cardiomyopathy

United States, Poland, Argentina, Australia, Belgium, France, Germany, Japan, Netherlands, Portugal, Spain, Sweden, United Kingdom, Canada, Czechia, Denmark, Hungary, Ireland, Norway, Korea, Republic of, Austria, Croatia, Israel, Latvia, Lithuan... and more
University Hospital Heidelberg
Charite University, Berlin, Germany; Goethe University; University Medicine Greifswald and other collaborators

Recruiting

DZHK TORCH-Plus is a Registry for Patients With Cardiomyopathies and Serves as Source for Cardiovascular Research Studies (TORCH-Plus)

Amyloidosis | HCM - Hypertrophic Cardiomyopathy | Arrhythmogenic Right Ventricular Cardiomyopathy | Inflammatory Cardiomyopathy | DCM - Dilated Cardiomyopathy | Non-ischemic Cardiomyopathy | HOCM - Hypertrophic Obstructive Cardiomyopathy | Left Ventricular Noncompaction Cardiomyopathy

Germany
German Heart Institute
Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK)

Unknown

Risk Stratification in Children and Adolescents With Primary Cardiomyopathy (RIKADA)

Dilated Cardiomyopathy | Hypertrophic Cardiomyopathy | Arrhythmogenic Right Ventricular Cardiomyopathy | Restrictive Cardiomyopathy | Left Ventricular Noncompaction | Primary Cardiomyopathy

Germany
Dennis M. McNamara, MD, MS
National Heart, Lung, and Blood Institute (NHLBI)

Recruiting

Impact of Bromocriptine on Clinical Outcomes for Peripartum Cardiomyopathy (REBIRTH)

Peripartum Cardiomyopathy, Postpartum

United States
University Medical Center Groningen
AstraZeneca

Completed

Identification of Disease Specific Pathways and Modifiers in Phospholamban R14del Cardiomyopathy (DECIPHER-PLN)

Heart Failure | Cardiomyopathy, Familial | Phospholamban R14del Cardiomyopathy

Netherlands

Clinical Trials on TTR Cardiomyopathy

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Liberia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations